Breaking News

Tris Pharma Launches Digital Health Business

Through licensing agreement with Braingaze aims to develop and commercialize digital products for ADHD.

Tris Pharma, Inc., a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and neurological disorders, has entered into a licensing agreement with Braingaze Ltd. and launched its new business, Tris Digital Health, which will focus on the development and commercialization of digital diagnostic and therapeutic products for neurological health conditions.  
 
Tris has secured exclusive rights to develop and commercialize Braingaze’s digital ADHD diagnostic platform in the U.S. and Canada. Braingaze is a digital health company developing technology-driven diagnostic and treatment solutions for cognitive disorders.  
  
Braingaze’s digital biomarker-based ADHD diagnostic tool was developed in Europe and carries the European CE Mark as a medical device. With input from the U.S. FDA, Tris Pharma will initiate clinical trials in the U.S. to further validate this technology as an objective ADHD diagnostic tool for clinical use in the U.S. and Canada. 
 
“Patients, caregivers and physicians deserve better tools to support accurate ADHD diagnosis beyond the currently available options,” said Ketan Mehta, founder and CEO at Tris Pharma. “We have launched Tris Digital Health to deliver on our long-term commitment to advance meaningful and beneficial healthcare for physicians, ADHD patients and caregivers. We are delighted to partner with Braingaze to launch this important endeavor and look forward to offering practitioners in the United States and Canada the opportunity to use and evaluate the benefits of this digital ADHD diagnostic platform.” 
  
“We’ve received enthusiastic feedback from European physicians who tell us that our novel diagnostic test is an improvement over subjective tools they relied on until now,” said Laszlo Bax, CEO and co-founder of Braingaze. “We are thrilled to partner with Tris, another leader in the ADHD space who has an exceptional track record with four commercialized medications, to extend the reach of our ADHD diagnostic solutions to patients who might benefit from it in the United States and Canada.” 

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters